Transaction Includes U.S. and Canadian Commercial Rights to FLAREX, NATACYN, TOBRADEX ST, VERKAZIA, ZERVIATE, and Non-Prescription Brands FRESHKOTE and Cationorm PLUS.
The company develops topical ophthalmic products.
They'll tackle conditions such as glaucoma and dry eye.
Get the most important news and business ideas for eyecare professionals every weekday from INVISION.
Advertisement